

2021

Issue 2



Newsletter 2 | 2021

## EPROPA: an update

### Index:

<i>EPROPA: an update</i>	1
<i>What is the EPROPA reference center?</i>	1
<i>The voice of the Italian / European Centers</i>	2
<i>Figures in April 2021</i>	3

Launched in December 2020, **EPROPA** (European Program for **R**outine testing of **P**atients with **A**dvanced lung cancer) is a program for European patients with advanced non-small cell lung cancer (NSCLC).



EPROPA is an effective diagnostic and therapeutic opportunity that allows patients to have a broad and complete molecular characterization with the optimization of the management of the biopsy material and the time required for the outcome of the molecular analysis.

### Team

### EPROPA



### WALCE

HQ based at Thoracic Oncology Unit (San Luigi Hospital)

Regione Gonzole, 10

10043 Orbassano (TO) (Italy)

Ph. +39 011 9026980

[info@womenagainstlungcancer.eu](mailto:info@womenagainstlungcancer.eu)

[www.womenagainstlungcancer.org](http://www.womenagainstlungcancer.org)



## What is the EPROPA reference center?

WALCE is located at the San Luigi Hospital in Orbassano (Turin-Italy), headquarter of the Molecular Biology Laboratory of the SCDU of Pathological Anatomy of the Department of Oncology of the University of Turin, where the analyzes will be carried out. WALCE together with the Reference Center will guarantee the quality and timely execution of the analyzes



## About us...

*“Three months after launching EPROPA program, 3 European countries are already active and are offering this opportunity to patients and 2 other countries will be soon.*

*Many patients have contacted us and, always involving the centers of reference, and we are pleased to have been of support in the diagnostic and therapeutic approach.*

*In addition to having identified target molecular alterations in many of the samples examined, a few days ago the first patient also benefited from the second objective of EPROPA, accessing a clinical trial available in another center, on the basis of the analysis conducted”*

**(Prof. Silvia Novello** - President WALCE and Head of Thoracic Oncology Unit - San Luigi Hospital Orbassano /Turin – Italy)



## The voice of the Italian Centers:




*“The study in NGS in our reality is not yet reimbursed and, for about three months thanks to EPROPA program, the reality of our patients with lung cancer has completely changed.*

*The effectiveness of this project confirms the need to centralize the molecular characterization in highly specialized centers with the availability of NGS and a dedicated team for the analysis and interpretation of the results with the aim of optimizing the diagnostic-therapeutic path of patients with lung cancer .”*

**(Dr. Claudio Sini** - John Paul II Hospital of Olbia - Medical Oncology and CPDO Unit)

## PARTNERS: Greece




**Korina Pateli Bell** - President of Fair Life, Greek lung cancer patient association, that with KEFI actively supports the promotion of EPROPA program in Greece .

*Thanks to all of you and your teams for dedication and continued efforts*

in **April 2021** the following numbers were reached:

**Number of patients registered: 42**  
**Number of centres registered: 13**  
**Number of active European countries: 3**



Molecular Tests in progress: 16

Molecular Analysis performed: 35

**Clinical Trial Enrollment: 1**

We examined SNVs, CNVs, gene fusions, and indels from 161 unique genes to help inform drug discovery research and clinical trial research programs. We performed library construction of DNA and RNA from formalin-fixed paraffin embedded (FFPE) tumour samples. We support patients' enrolment within biomarker-driven clinical trials available in Europe.

# WALCE

HQ based at Thoracic Oncology Unit (San Luigi Hospital)  
Regione Gonzole, 10  
10043 Orbassano (TO) | Italy

Ph. +39 011 9026980  
info@womenagainstlungcancer.eu  
Facebook | Twitter



Fighting Lung Cancer Together.

[www.womenagainstlungcancer.org](http://www.womenagainstlungcancer.org)

## About WALCE

**WALCE** (Women Against Lung Cancer in Europe) is a non-profit Organisation based in Italy and networking at European level, founded in 2006 with the primary aim to increase women's awareness about the significant incidence and mortality of lung cancer in female population and to support patients affected by this disease (and their families).

WALCE currently provides accurate and updated information about lung cancer in terms of prevention, diagnosis and treatment, and it wants to promote communication strategies aim to aware public opinion and decision makers on damages of smoking. WALCE is mainly involved in: information and education dedicated to patients and their families, patient support programs and primary prevention.



## More infos

### How can you get any information?

Check the website: <https://www.epropa.eu/en/>

Here you can find information about:

- **participating procedures;**
- **tumour sample shipment instructions;**
- **molecular analysis and clinical trials.**

**Biological Material:** the samples for analysis must be preferably FFPE blocks of tumor tissue available (which will be returned at the end of the analysis) or 20 blank sections of the same and a paper copy of the report must be added. We provide to evaluate the material: in case of its inadequacy, the analysis will not be carried out. In case of its insufficiency, if possible, a further sending will be requested.

### How can you enter in EPROPA platform?

- 1) Access to <https://www.epropa.eu/en>
- 2) Download the form and e-mail to: [stefania.vallone@womenagainstlungcancer.eu](mailto:stefania.vallone@womenagainstlungcancer.eu)
- 3) You will receive an email to finalize the process registering to the website platform: [www.epropa.eu/portal](http://www.epropa.eu/portal)

PROMOTED BY



ENDORSED BY



SUPPORTED BY UNRESTRICTED GRANTS OF



In Greece:

